Big pharma’s biggest spenders revealed: 2022 edition

A quiet time on the acquisition front for several big pharma names caused this group’s combined M&A and R&D bill to drop for the second year in a row in 2022. Even Pfizer’s buying spree failed to prop up the numbers, with the $157bn deployed the lowest number since 2018.